CXM: A new tool for mapping breast cancer risk in the tumor microenvironment

Cancer Research

Volumn 74, Issue 22, 2014, Pages 6419-6429

  Flister, Michael J ^a   Endres, Bradley T ^a   Rudemiller, Nathan ^a   Sarkis, Allison B ^a   Santarriaga, Stephanie ^a   Roy, Ishan ^a   Lemke, Angela ^a   Geurts, Aron M ^a   Moreno, Carol ^a   Ran, Sophia ^b   Tsaih, Shirng Wern ^a   De Pons, Jeffery ^a   Carlson, Daniel F ^c   Tan, Wenfang ^d,e   Fahrenkrug, Scott C ^c,d,e   Lazarova, Zelmira ^a   Lazar, Jozef ^a   North, Paula E ^a   LaViolette, Peter S ^a   Dwinell, Michael B ^a   Shull, James D ^f,g,h   Jacob, Howard J ^a   more..

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RECOMBINETICS INC   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^h UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GENETICS; CANCER GROWTH; CANCER MODEL; CANCER RISK; CHROMOSOME 3; CONSOMIC XENOGRAFT MODEL; CONTROLLED STUDY; EMBRYO; FEMALE; GENE SEQUENCE; GENETIC VARIABILITY; GENOME ANALYSIS; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS; NONHUMAN; RAT; RAT STRAIN; RISK ASSESSMENT; STRAIN DIFFERENCE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; BREAST NEOPLASMS; CANCER TRANSPLANTATION; GENETICS; HUMAN; LYMPHANGIOGENESIS; MALE; PATHOLOGY; QUANTITATIVE TRAIT LOCUS; RISK; TUMOR CELL LINE; VASCULARIZATION; XENOGRAFT;

7,12 DIMETHYLBENZ[A]ANTHRACENE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; LYMPHANGIOGENESIS; MALE; NEOPLASM TRANSPLANTATION; QUANTITATIVE TRAIT LOCI; RATS; RISK; TRANSPLANTATION, HETEROLOGOUS; TUMOR MICROENVIRONMENT;

EID: 84918497707     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3212     Document Type: Article

References (58)

1. Peto J, Mack TM High constant incidence in twins and other relatives of women with breast cancer. Nat Genet 2000; 26:411-4.
2. Rosman DS, Kaklamani V, Pasche B. New insights into breast cancer genetics and impact on patient management. Curr Treat Options Oncol 2007; 8:61-73.
3. Pharoah PD, Antoniou A, Bobrow M., Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002; 31:33-6.
4. Hartman M, Lindstrom L, Dickman P.W., Adami HO, Hall P, Czene K. Is breast cancer prognosis inherited? Breast Cancer Res 2007; 9:R39.
5. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M., Dennis J, Milne RL, et al Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 2013; 45:353-61, 361e351-352.
6. Rafiq S, Tapper W, Collins A., Khan S, Politopoulos I, Gerty S., et al. Identification of inherited genetic variations influencing prognosis in early-onset breast cancer. Cancer Res 2013; 73:1883-91.
7. Park YG, Zhao X, Lesueur F., Lowy DR, Lancaster M, Pharoah P, et al Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet 2005; 37:1055-62.
8. Shu XO, Long J, Lu W., Li C, Chen WY, Delahanty R, et al Novel genetic markers of breast cancer survival identified by a genome-wide association study. Cancer Res 2012; 72:1182-9.
9. Minn AJ, Gupta GP, Siegel P.M., Bos PD, Shu W, Giri DD, et al Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518-24.
10. Gupta GP, Nguyen DX, Chiang A.C., Bos PD, Kim JY, Nadal C, et al Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007; 446:765-70.
11. Maae E, Andersen RF, Steffensen K.D., Jakobsen EH, Brandslund I, Sorensen FB, et al Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer. Anticancer Res 2012; 32:3619-27.
12. Smith KC, Bateman AC, Fussell H.M., Howell WM. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 2004; 31:167-73.
13. Cowley AW J.r., Roman RJ, Jacob HJ Application of chromosomal substitution techniques in gene-function discovery. J Physiol 2004; 554:46-55.
14. Carlson DF, Fahrenkrug SC, Hackett PB Targeting DNA with fingers and TALENs. Mol Ther Nucleic Acids 2012; 1:e3.
15. Mashimo T, Takizawa A, Voigt B., Yoshimi K, Hiai H, Kuramoto T., et al. Generation of knockout rats with X-linked severe combined immunodeficiency (X-SCID) using zinc-finger nucleases. PLoS ONE 2010; 5: e8870.
16. Adamovic T, McAllister D, Wang T., Adamovic D, Rowe JJ, Moreno C, et al Identification of novel carcinogen-mediated mammary tumor susceptibility loci in the rat using the chromosome substitution technique. Genes Chromosomes Cancer 2010; 49:1035-45.
17. Wendell DL, Gorski J. Quantitative trait loci for estrogen-dependent pituitary tumor growth in the rat. Mamm Genome 1997; 8:823-9.
18. Schaffer BS, Lachel CM, Pennington K.L., Murrin CR, Strecker TE, Tochacek M, Genetic bases of estrogen-induced tumorigenesis in the rat: mapping of loci controlling susceptibility to mammary cancer in a Brown Norway x ACI intercross. Cancer Res 2006; 66:7793-800.
19. Kurz SG, Hansen KK, McLaughlin M.T., Shivaswamy V., Schaffer BS, Gould KA, et al. Tissue-specific actions of the Ept1, Ept2, Ept6, and Ept9 genetic determinants of responsiveness to estrogens in the female rat. Endocrinology 2008; 149:3850-9.
20. Geurts AM, Cost GJ, Freyvert Y, Zeitler B., Miller JC, Choi VM, et al. Knockout rats via embryo microinjection of zinc-finger nucleases. Science 2009; 325:433.
21. Volk LD, Flister MJ, Bivens C.M., Stutzman A., Desai N, Trieu V, et al Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothe-lial growth factor A therapy. Neoplasia 2008; 10:613-23.
22. Faraji F, Hu Y, Wu G., Goldberger NE, Walker RC, Zhang J, et al An integrated systems genetics screen reveals the transcriptional structure of inherited predisposition to metastatic disease. Genome Res 2014; 24:227-40.
23. Whitehurst B, Flister MJ, Bagaitkar J, Volk L., Bivens CM, Pickett B, et al. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. Int J Cancer 2007; 121:2181-91.
24. Hall KL, Volk-Draper LD, Flister M.J., Ran S. New model of macrophage acquisition of the lymphatic endothelial phenotype. PLoS ONE 2012; 7: e31794.
25. Mattson DL, Lund H, Guo C., Rudemiller N, Geurts AM, Jacob H. Genetic mutation of recombination activating gene 1 in Dahl saltsensitive rats attenuates hypertension and renal damage. Am J Physiol Regul Integr Comp Physiol 2013; 304:R407-14.
26. Flister MJ, Prisco SZ, Sarkis A.B., O'Meara CC, Hoffman M, Wendt-Andrae J, et al. Identification of hypertension susceptibility loci on rat chromosome 12. Hypertension 2012; 60:942-8.
27. Atanur SS, Diaz AG, Maratou K, Sarkis A., Rotival M, Game L, et al Genome sequencing reveals loci under artificial selection that underlie disease phenotypes in the laboratory rat. Cell 2013; 154:691-703.
28. Gibbs RA, Weinstock GM, Metzker M.L., Muzny DM, Sodergren EJ, Scherer S, et al Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature 2004; 428:493-521.
29. Lifsted T, Le Voyer T, Williams M, Muller W., Klein-Szanto A, Buetow KH, et al Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer 1998; 77:640-4.
30. Ohbo K, Suda T, Hashiyama M., Mantani A, Ikebe M, Miyakawa K., et al. Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain. Blood 1996; 87:956-67.
31. Flister MJ, Wilber A, Hall K.L., Iwata C., Miyazono K, Nisato RE, et al Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1. Blood 2010; 115: 418-29.
32. Pandey J, Wendell DL Angiogenesis and capillary maturation pheno-types associated with the Edpm3 locus on rat chromosome 3. Mamm Genome 2006; 17:49-57.
33. Ran S, Volk L, Hall K., Flister MJ. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 2010; 17:229-51.
34. Auerbach R, Lewis R, Shinners B., Kubai L, Akhtar N. Angiogenesis assays: a critical overview. Clin Chem 2003; 49:32-40.
35. Flister MJ, Volk LD, Ran S. Characterization of Prox1 and VEGFR-3 expression and lymphatic phenotype in normal organs of mice lacking p50 subunit of NF-kappaB. Microcirculation 2011; 18:85-101.
36. Ruivenkamp CA, van Wezel T, Zanon C, Stassen AP, Vlcek C, Csikos T, et al. Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nat Genet 2002; 31:295-300.
37. Zhou J, Nagarkatti PS, Zhong Y, Zhang J., Nagarkatti M. Implications of single nucleotide polymorphisms in CD44 exon 2 for risk of breast cancer. Eur J Cancer Prev 2011; 20:396-402.
38. Zhou J, Nagarkatti PS, Zhong Y, Creek K., Zhang J, Nagarkatti M. Unique SNP in CD44 intron 1 and its role in breast cancer development. Anticancer Res 2010; 30:1263-72.
39. Jiang L, Deng J, Zhu X., Zheng J, You Y, Li N., et al. CD44 rs13347 C>T polymorphism predicts breast cancer risk and prognosis in Chinese populations. Breast Cancer Res 2012; 14:R105.
40. Tulsyan S, Agarwal G, Lal P., Agrawal S, Mittal RD, Mittal B. CD44 gene polymorphisms in breast cancer risk and prognosis: a study in North Indian population. PLoS ONE 2013; 8:e71073.
41. Cao G, Savani RC, Fehrenbach M, Lyons C., Zhang L, Coukos G, et al Involvement of endothelial CD44 during in vivo angiogenesis. Am J Pathol 2006; 169:325-36.
42. Lopez JI, Camenisch TD, Stevens M.V., Sands BJ, McDonald J, Schroeder JA. CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res 2005; 65:6755-63.
43. Diaz LK, Zhou X, Wright E.T., Cristofanilli M., Smith T, Yang Y, et al CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res 2005; 11:3309-14.
44. Berner HS, Suo Z, Risberg B., Villman K, Karlsson MG, Nesland JM Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas. Histopathology 2003; 42:546-54.
45. Takahashi T, Takahashi K, Mernaugh R.L., Tsuboi N., Liu H, Daniel TO. A monoclonal antibody against CD148, a receptor-like tyrosine phos-phatase, inhibits endothelial-cell growth and angiogenesis. Blood 2006; 108:1234-42.
46. Takahashi T, Takahashi K, St John PL, Fleming PA, Tomemori T, Watanabe T, et al A mutant receptor tyrosine phosphatase, CD148, causes defects in vascular development. Mol Cell Biol 2003; 23:1817-31.
47. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007; 8:341-52.
48. Hunter K. Host genetics influence tumour metastasis. Nat Rev Cancer 2006; 6:141-6.
49. Bodenstine TM, Welch DR Metastasis suppressors and the tumor microenvironment. Cancer Microenviron 2008; 1:1-11.
50. Flister MJ, Hoffman MJ, Reddy P, Jacob H.J., Moreno C. Congenic mapping and sequence analysis of the Renin locus. Hypertension 2013; 61:850-6.
51. Hoffman MJ, Flister MJ, Nunez L, Xiao B., Greene AS, Jacob HJ, et al. Female-specific hypertension Loci on rat chromosome 13. Hypertension 2013; 62:557-63.
52. Flister MJ, Tsaih SW, O'Meara CC, Endres B, Hoffman M.J., Geurts AM, et al. Identifying multiple causative genes at a single GWAS locus. Genome Res 2013; 23:1996-2002.
53. Rangel-Filho A., Lazar J, Moreno C., Geurts A, Jacob HJ. Rab38 modulates proteinuria in model of hypertension-associated renal disease. J Am Soc Nephrol 2013; 24:283-92.
54. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-64.
55. Baek KH, Zaslavsky A, Lynch R.C., Britt C., Okada Y, Siarey RJ, et al Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 2009; 459:1126-30.
56. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25:581-611.
57. Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 2007; 18:x3-10.
58. Chen YG, Forsberg MH, Khaja S, Ciecko A.E., Hessner MJ, Geurts AM. Gene targeting in NOD mouse embryos using zinc-finger nucleases. Diabetes 2013; 63:68-74.